Skip to main content
. 2018 Mar 12;18:234–240. doi: 10.1016/j.dib.2018.03.033

Table 3.

TAG profiles of MDA-MB-231 breast cancer cells depleted in ATGL and treated with exogenous DHA, sPLA2 or both.

TAG composition (% of total)a
TAG speciesb SCRc siATGL SCR+DHA siATGL+DHA SCR+DHA+sPLA2 siATGL+DHA+sPLA2
46:0 0.30 ± 0.03 0.42 ± 0.02 0.031 ± 0.003 0.05 ± 0.01 0.03 ± 0.01 0.03 ± 0.01
48:0 1.3 ± 0.1 1.9 ± 0.1 0.11 ± 0.02 0.16 ± 0.01 0.08 ± 0.01 0.14 ± 0.01
48:1 1.19 ± 0.02 1.5 ± 0.1 0.16 ± 0.02 0.26 ± 0.04 0.15 ± 0.03 0.17 ± 0.03
50:0 3.8 ± 0.3 5.41 ± 0.03 0.3 ± 0.1 0.5 ± 0.1 0.2 ± 0.1 0.5 ± 0.1
50:1 5.1 ± 0.2 6.8 ± 0.1 0.5 ± 0.1 1.1 ± 0.2 0.6 ± 0.1 0.7 ± 0.1
50:2 1.94 ± 0.04 2.4 ± 0.2 0.3 ± 0.1 0.6 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
52:0 6.3 ± 0.4 7.9 ± 0.2 0.5 ± 0.1 0.9 ± 0.1 0.4 ± 0.1 0.75 ± 0.02
52:1 11.0 ± 1.0 12.0 ± 1.0 1.1 ± 0.2 2.2 ± 0.3 1.1 ± 0.2 1.6 ± 0.1
52:2 8.0 ± 1.0 8.9 ± 0.4 1.4 ± 0.1 2.1 ± 0.3 1.3 ± 0.2 1.4 ± 0.2
52:3 2.3 ± 0.2 2.7 ± 0.2 0.6 ± 0.1 0.7 ± 0.1 0.5 ± 0.1 0.4 ± 0.1
52:4 0.68 ± 0.03 0.7 ± 0.1 0.20 ± 0.03 0.21 ± 0.02 0.21 ± 0.03 0.19 ± 0.02
54:0 1.7 ± 0.2 1.75 ± 0.03 0.09 ± 0.01 0.2 ± 0.1 0.07 ± 0.01 0.1327 ± 0.0002
54:1 8.1 ± 0.4 8.0 ± 1.0 0.7 ± 0.1 1.3 ± 0.2 0.7 ± 0.1 1.2 ± 0.2
54:2 5.5 ± 0.3 5.4 ± 0.2 0.6 ± 0.1 1.3 ± 0.2 0.9 ± 0.1 1.02 ± 0.01
54:3 5.0 ± 1.0 5.0 ± 1.0 1.1 ± 0.1 1.5 ± 0.2 1.2 ± 0.1 0.98 ± 0.01
54:4 2.5 ± 0.2 2.3 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.7 ± 0.1
54:5 2.1 ± 0.04 1.7 ± 0.1 n.d. n.d. n.d. n.d.
54:6 1.4 ± 0.2 1.11 ± 0.04 2.5 ± 0.4 2.9 ± 0.3 2.4 ± 0.4 2.3 ± 0.2
54:7 0.21 ± 0.03 0.16 ± 0.02 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.2 ± 0.1
56:0 1.0 ± 0.1 1.10 ± 0.02 0.06 ± 0.01 0.11 ± 0.04 n.d. 0.11 ± 0.02
56:1 2.0 ± 0.1 1.6 ± 0.1 0.14 ± 0.01 0.25 ± 0.03 0.12 ± 0.02 0.169 ± 0.004
56:2 1.9 ± 0.1 1.7 ± 0.1 0.23 ± 0.02 0.40 ± 0.1 0.23 ± 0.03 0.25 ± 0.02
56:3 1.50 ± 0.03 1.28 ± 0.03 0.20 ± 0.03 0.34 ± 0.04 0.32 ± 0.04 0.30 ± 0.01
56:6 3.9 ± 0.4 2.4 ± 0.04 4.0 ± 1.0 3.6 ± 0.4 5.0 ± 1.0 4.7 ± 0.3
56:7 1.7 ± 0.3 1.1 ± 0.1 5.0 ± 1.0 4.6 ± 0.3 6.9 ± 0.4 6.3 ± 0.4
58:1 1.91 ± 0.02 1.68 ± 0.04 0.11 ± 0.02 0.21 ± 0.04 0.13 ± 0.02 0.22 ± 0.04
58:2 1.2 ± 0.1 1.02 ± 0.01 0.12 ± 0.01 0.20 ± 0.02 0.12 ± 0.02 0.13 ± 0.01
58:3 0.62 ± 0.04 0.51 ± 0.03 0.06 ± 0.01 0.11 ± 0.01 0.11 ± 0.02 0.14 ± 0.04
58:5 1.7 ± 0.2 0.8 ± 0.1 0.3 ± 0.1 0.26 ± 0.02 0.7 ± 0.2 n.d.
58:6 3.0 ± 0.4 1.9 ± 0.3 n.d. n.d. n.d. n.d.
58:7 2.1 ± 0.3 1.7 ± 0.4 4.9 ± 0.4 4.9 ± 0.2 7.0 ± 1.0 6.9 ± 0.3
58:8 0.9 ± 0.1 0.6 ± 0.2 3.4 ± 0.4 3.4 ± 0.2 5.2 ± 0.2 4.9 ± 0.1
58:9 0.2 ± 0.1 0.2 ± 0.1 1.0 ± 0.1 0.92 ± 0.01 1.8 ± 0.1 1.7 ± 0.1
58:10 n.d. 0.07 ± 0.03 0.82 ± 0.01 0.78 ± 0.02 1.267 ± 0.002 1.23 ± 0.01
58:11 n.d. n.d. 0.9 ± 0.1 0.88 ± 0.03 1.1 ± 0.1 1.2 ± 0.1
58:12 n.d. 0.03 ± 0.01 2.7 ± 0.4 2.9 ± 0.3 2.0 ± 0.4 2.1 ± 0.1
60:1 2.3 ± 0.1 1.85 ± 0.02 0.13 ± 0.04 0.22 ± 0.03 0.15 ± 0.03 0.26 ± 0.03
60:2 1.50 ± 0.02 1.21 ± 0.02 0.14 ± 0.01 0.20 ± 0.02 0.16 ± 0.02 0.21 ± 0.04
60:3 0.60 ± 0.02 0.47 ± 0.02 0.05 ± 0.01 0.10 ± 0.02 0.09 ± 0.01 0.10 ± 0.02
60:4 0.4 ± 0.1 0.3 ± 0.10 n.d. 0.05 ± 0.01 0.09 ± 0.02 0.08 ± 0.01
60:10 0.1 ± 0.1 0.11 ± 0.04 1.9 ± 0.1 1.76 ± 0.01 3.1 ± 0.2 3.2 ± 0.1
60:12 1.1 ± 0.4 0.45 ± 0.03 18.7 ± 0.3 18.0 ± 1.0 15.0 ± 1.0 16.0 ± 0.4
60:13 0.1 ± 0.1 0.062 ± 0.004 3.0 ± 0.4 3.1 ± 0.1 2.0 ± 1.0 2.5 ± 0.1
62:1 1.0 ± 0.1 0.76 ± 0.03 n.d. 0.08 ± 0.01 n.d. 0.10 ± 0.01
62:2 0.9 ± 0.1 0.620 ± 0.003 0.06 ± 0.02 0.08 ± 0.01 0.08 ± 0.02 0.12 ± 0.01
62:3 0.43 ± 0.02 0.31 ± 0.01 0.04 ± 0.01 0.050 ± 0.004 0.07 ± 0.02 0.07 ± 0.01
62:11 n.d. 0.04 ± 0.01 1.0 ± 0.1 n.d. 1.0 ± 0.1 1.2 ± 0.1
62:12 0.32 ± 0.04 0.3 ± 0.1 8.7 ± 0.2 6.6 ± 0.4 8.2 ± 0.1 7.0 ± 1.0
62:13 0.5 ± 0.2 0.43 ± 0.01 17.3 ± 1.3 14.6 ± 1.1 15.59 ± 0.02 15.0 ± 1.0
62:14 n.d. n.d. 2.7 ± 0.4 2.6 ± 0.2 2.2 ± 0.4 2.4 ± 0.2
66:18 0.18 ± 0.04 0.18 ± 0.01 12.3 ± 2.2 11.2 ± 1.4 7.0 ± 2.0 7.0 ± 1.0
a

The lipidomic data is presented as mean percentages of each species per total detected species and normalised to total cellular protein.

b

TAG species are presented according to the number of carbon atoms and double bonds.

c

MDA-MB-231 cells were reverse transfected with ATGL-targeting siRNA (siATGL) or non-targeting scrambled siRNA (SCR) and treated with 100 µM DHA and 10 nM sPLA2 in complete medium for 48 h. Cell lysates were collected for UPLC/MS analysis. Values are means ± SEM of three independent experiments; n.d., not determined.